TAFI activity in coronary artery disease: A contribution to the current discussion on TAFI assays

Thromb Haemost 2006; 96(02): 236-237
DOI: 10.1160/TH06-06-0295

Letter to the Editor

Schattauer GmbH

Autor*innen

Verena Schroeder

¹Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital, Bern, Switzerland
Marianne Wilmer

²Pentapharm Ltd, Basel, Switzerland
Beatrice Buehler

²Pentapharm Ltd, Basel, Switzerland
Hans P. Kohler

¹Laboratory for Thrombosis Research, Department of Clinical Research, Inselspital, University Hospital, Bern, Switzerland

References
1 Nesheim ME. TAFI. Review. Fibrinol Proteol 1999; 13: 72-7.
2 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
3 Leurs J, Hendriks D. CarboxypeptidaseU (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
4 Gils A, Alessi MC, Brouwers E. et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
5 Guimaraes AHC, van Tilburg NH, Vos HL. et al. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004; 124: 659-65.
6 Verdú J, Marco P, Benlloch S. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) polymorphisms and plasma TAFI levels measured with an ELISA insensitive to isoforms in patients with venous thromboembolic disease (VTD). Thromb Haemost 2006; 95: 585-6.
7 Schroeder V, Chatterjee T, Mehta H. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002; 88: 1020-5.